Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Neurofibroma, Plexiform 1Nerve Sheath Neoplasms 1Lymphedema 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × pirfenidone × Clear all
NCT04243837 2024-04-23

LYT-100 in Patients With BCRL

PureTech

Phase 2 Terminated
50 enrolled 9 charts

Lymphedema

NCT00076102 2018-04-23

Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
36 enrolled 13 charts
CNS

Neurofibromatosis 1, Nerve Sheath Neoplasms, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡